Rheumatoid Arthritis

  • Christopher V. Tehlirian
  • Joan M. Bathon


Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease that affects all ethnic groups throughout the world. Females are 2.5 times more likely to be affected than males. The onset of disease can occur at any age but peak incidence occurs within the fourth and fifth decades of life. The average annual incidence of RA in the United States is 0.5 per 1000 persons per year (1). The overall prevalence of RA is 1% to 2%, and it steadily increases to 5% in women by the age of 70 (2). However, there are differences in prevalence rates of RA in various ethnic groups, ranging from 0.1% in rural Africans to 5% in Pima or Chippewa Indians (3). Many factors contribute to the risk of developing RA and are reviewed in the following chapter (see Chapter 6B).


Rheumatoid Arthritis Rheumatoid Arthritis Patient Human Leukocyte Antigen Rheumatoid Factor Joint Damage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Drosos A. Epidemiology of rheumatoid arthritis. Autoimmun Rev 2004;3(Suppl 1):S20–S22.PubMedGoogle Scholar
  2. 2.
    Symmons D, Barrett E, Bankhead C, et al. The occurrence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994;33:735–739.CrossRefPubMedGoogle Scholar
  3. 3.
    Hochberg M, Spector T. Epidemiology of rheumatoid arthritis: update. Epidemiol Rev 1990;12:247–252.PubMedGoogle Scholar
  4. 4.
    Jacoby R, Cosh J, Jayson M. Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study with 100 patients with 11 years of follow-up. Br Med J 1973;2: 96–100.CrossRefPubMedGoogle Scholar
  5. 5.
    Turesson C, O’Fallon W, Crowson C, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003;62:722–727.CrossRefPubMedGoogle Scholar
  6. 6.
    Schellekens G, Visser H, de Jong B, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43: 155–163.CrossRefPubMedGoogle Scholar
  7. 7.
    Nielen M, van Schaardenburg D, Reesink H, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380–386.CrossRefPubMedGoogle Scholar
  8. 1.
    Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205–1213.CrossRefPubMedGoogle Scholar
  9. 2.
    Gregersen PK. Pathways to gene identification in rheumatoid arthritis: PTPN22 and beyond. Immunol Rev 2005;204:74–86.CrossRefPubMedGoogle Scholar
  10. 3.
    Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54:38–46.CrossRefPubMedGoogle Scholar
  11. 4.
    Cambridge G, Edwards JC. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6:394–403.CrossRefPubMedGoogle Scholar
  12. 5.
    Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol 2004;16:246–253.CrossRefPubMedGoogle Scholar
  13. 6.
    Kremer JM. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J Clin Rheumatol 2005;11(Suppl):S55–S62.CrossRefPubMedGoogle Scholar
  14. 7.
    Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 2001;45:101–106.Google Scholar
  15. 8.
    Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005;208:228–251.CrossRefPubMedGoogle Scholar
  16. 9.
    Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356–361.CrossRefPubMedGoogle Scholar
  17. 1.
    O’Dell J, Haire CE, Erikson N, et al. Treatment of rheumatoid arhtritis with methotrexate alone, sulfasalazine and hydroxychloroquinne, or a combination of all three medications. N Engl J Med 1996;334:1287–1291.CrossRefPubMedGoogle Scholar
  18. 2.
    Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulfasalzine alone in early rheumatoid arthritis. Lancet 1997;350:309–338.CrossRefPubMedGoogle Scholar
  19. 3.
    Landewé RB, Boers M, Verhoeven AC, et al. COBA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief inter-vention. Arthritis Rheum 2002;46:347–356.CrossRefPubMedGoogle Scholar
  20. 4.
    Andersen PA, West SG, O’Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985;103:489–496.PubMedGoogle Scholar
  21. 5.
    Weinblatt ME, Polisson R, Blotner SD, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993;36:613–619.CrossRefPubMedGoogle Scholar
  22. 6.
    Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercpt and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586– 1593.CrossRefPubMedGoogle Scholar
  23. 7.
    Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with luflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159: 2542–2550.CrossRefPubMedGoogle Scholar
  24. 8.
    Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259–266.CrossRefPubMedGoogle Scholar
  25. 9.
    Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993;23: 82–91.CrossRefPubMedGoogle Scholar
  26. 10.
    Clark P, Casas E, Tugwell P, et al. Hydroxychloroquinne compared with placebo in rheumatoid arhtritis. A randomized controlled trial. Ann Intern Med 1993;119: 1067–1071.Google Scholar
  27. 11.
    Gadangi P, Langaker M, Naime D, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996;156:1937–1941.PubMedGoogle Scholar
  28. 12.
    Alarcon GS. Minocycline for the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:489–499.CrossRefPubMedGoogle Scholar
  29. 13.
    Lehman AJ, Esdaile JM, Klinkhoff AV, et al. A 48-week, randomized, double-blind, double-observer, placebo- controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum 2005;53:1360–1370.CrossRefGoogle Scholar
  30. 14.
    Marchesoni A, Battafarano N, Arreghini M, et al. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology 2003;42:1545–1549.CrossRefPubMedGoogle Scholar
  31. 15.
    Gerards AH, Landewe RB, Prins AP, et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 2003;62:291–296.CrossRefPubMedGoogle Scholar
  32. 16.
    Moreland LW, Weinblatt ME, Keystone EC, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006; 33:854–861.PubMedGoogle Scholar
  33. 17.
    Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arhtritis treated with biologic agents. Arthritis Rheum 2005;52:3403–3412.CrossRefPubMedGoogle Scholar
  34. 18.
    Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2005;295:2275–2285.CrossRefGoogle Scholar
  35. 19.
    Wolf F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740– 1751.CrossRefGoogle Scholar
  36. 20.
    Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63: 1062–1068.CrossRefPubMedGoogle Scholar
  37. 21.
    Bresnihan B, Newmark R, Robbins S, et al. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 2004;31:1103– 1111.PubMedGoogle Scholar
  38. 22.
    Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114–1123.CrossRefPubMedGoogle Scholar
  39. 23.
    Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572–2581.CrossRefPubMedGoogle Scholar
  40. 24.
    Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390–1400.CrossRefPubMedGoogle Scholar
  41. 25.
    Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:613–620.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Christopher V. Tehlirian
    • 1
  • Joan M. Bathon
    • 2
  1. 1.Department of Medicine, Division of Clinical and Molecular RheumatologyJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of Medicine, Johns Hopkins Arthritis CenterJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations